Johnson & Johnson Gets FDA OK For Spravato as Monotherapy
J&J on Tuesday said the green light makes Spravato the first and only monotherapy for adults with major depressive disorder who have had an inadequate response to at least two oral antidepressants.
FDA approves standalone use of J&J's ketamine-derived depression treatment
The U.S. Food and Drug Administration has expanded the approval for Johnson & Johnson's nasal spray Spravato to allow its ...
FDA approves Johnson & Johnson’s nasal spray for depression as standalone treatment
Spravato is now the first-ever standalone therapy for treatment-resistant depression, and is on its way to becoming a ...
US FDA approves J&J's ketamine-based therapy to treat depression
The U.S. Food and Drug Administration approved Johnson & Johnson's ketamine-based nasal spray Spravato, to treat adults with ...
What Analysts Think of Johnson & Johnson Stock Ahead of Earnings
Johnson & Johnson is set to report earnings before the bell Wednesday, with analysts expecting revenue and profit growth from ...
Controlled drug Ketamine a lifeline for patients with severe depression in Singapore
SINGAPORE (The Straits Times/ANN): Ketamine, the controlled drug best known as a horse tranquilliser or party supplement, has ...
Kara Margolis: We are in a mental health crisis. A ‘moonshot’ is needed.
Emerging research in mental health is showing how little we know and thus how much work needs to be done, including in how ...
Hold Rating for Johnson & Johnson Amid Modest Growth Outlook and Legal Uncertainties
In a report released today, Tim Anderson from Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research ...
S&P Places Johnson & Johnson on CreditWatch Negative
S&P Global Ratings placed Johnson & Johnson on CreditWatch with negative implications, citing its nearly $15 billion deal to acquire mental-illness drug developer Intra-Cellular Therapies.